Kevin Sayer Sells 26,756 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of the company’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the sale, the insider owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of DexCom stock opened at $75.14 on Thursday. The stock’s fifty day simple moving average is $72.86 and its 200 day simple moving average is $69.05. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $28.99 billion, a PE ratio of 32.11, a PEG ratio of 1.23 and a beta of 1.45. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm earned $0.32 earnings per share. The company’s revenue was up 15.0% on a year-over-year basis. On average, research analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent analyst reports. Bank of America cut their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Truist Financial raised their target price on shares of DexCom from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Benchmark reaffirmed a “buy” rating on shares of DexCom in a research note on Tuesday, June 23rd. Finally, Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $85.40.

Institutional Trading of DexCom

A number of institutional investors have recently modified their holdings of DXCM. Trust Co. of Vermont grew its holdings in shares of DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after buying an additional 145 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in DexCom by 15.4% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock valued at $77,000 after acquiring an additional 153 shares in the last quarter. V Square Quantitative Management LLC boosted its position in DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after acquiring an additional 172 shares during the last quarter. Essex Financial Services Inc. boosted its position in DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after acquiring an additional 175 shares during the last quarter. Finally, IFP Advisors Inc grew its stake in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.